Insider Transactions
| Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Aug 12, 2021 | Director, President and CEO | Form 4/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 34,938 | -- | -- | |
| Aug 12, 2021 | SVP Global Operations and R&D | Form 4/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 11,406 | -- | 33,228 | |
| Aug 12, 2021 | SVP Global Operations and R&D | Form 4/A | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 3,347 | $27.29 | 29,881 | |
| Aug 12, 2021 | SVP Global Operations and R&D | Form 4/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 9,834 | -- | -- | |
| Aug 12, 2021 | EVP and CFO | Form 4/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 10,946 | -- | 79,254 | |
| Aug 12, 2021 | EVP and CFO | Form 4/A | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 4,173 | $27.29 | 75,081 | |
| Aug 12, 2021 | EVP and CFO | Form 4/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 9,437 | -- | -- | |
| Jul 21, 2021 | SVP/GM, Vascular Access | Form 4/A | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 11,923 | -- | 11,923 | |
| Jul 21, 2021 | SVP and General Counsel | Form 4/A | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 6,197 | -- | 6,197 | |
| Jul 21, 2021 | SVP and General Counsel | Form 4/A | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 8,418 | -- | 8,418 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.